Safety and Efficacy of Relamorelin Administered to Participants With Vomiting Symptoms and Moderate to Severe Diabetic Gastroparesis

Phase 2

Completed

• Conditions: Diabetes Mellitus; Diabetes Mellitus Complications; Gastroparesis
• Interventions: Drug: Relamorelin; Drug: Placebo

• Registration Number: NCT02357420
• Lead Sponsor: Allergan

Brief Summary

The purpose of this study is to evaluate the effects of multiple dose regimens of relamorelin on vomiting episodes, gastric emptying and gastroparesis symptoms in participants with Type 1 and Type 2 diabetes mellitus and gastroparesis. Study drug (relamorelin and placebo) will be administered subcutaneously in a blinded fashion.

Detailed Description

Not available

Study Timeline

• Study Start: 2015-01-29
• Study First Submitted: 2015-01-29
• Study First Submitted QC: 2015-02-05
• Study First Posted: 2015-02-06
• Disposition First Submitted: 2016-02-16
• Disposition First Submitted QC: 2016-02-16
• Disposition First Posted: 2016-03-15
• Primary Completion: 2016-06-09
• Study Completion: 2016-06-09
• Status Verified: 2019-06
• Results First Submitted: 2019-07-01
• Results First Submitted QC: 2019-07-01
• Last Update Submitted: 2019-07-01
• Results First Posted: 2019-07-24
• Last Update Posted: 2019-07-24

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 393

Inclusion Criteria

• Type 1 diabetes mellitus (T1DM) or Type 2 diabetes mellitus (T2DM) with stable glycemic control and Hemoglobin A1c (HbA1c) ≤11% at screening.
• Diabetic gastroparesis (DG), defined as at least a 3-month history of symptoms suggestive of gastroparesis on an ongoing basis (e.g., vomiting, nausea, early satiety, bloating, or epigastric or abdominal pain).
• Gastroparesis Cardinal Symptom Index Daily Diary (GCSI-DD) score ≥2.6 at least once during the Screening Period (Visits 1-2).
• At least 2 vomiting episodes during the ~2 weeks prior to the first screening visit (Visit 1), as ascertained by patient history.
• Delayed Gastric Emptying (GE) confirmed at screening by abnormal Gastric Emptying Breath Test (GEBT), defined as GE half-time (t1/2) ≥79 minutes (the 80th percentile of normative data). At least 50% of patients enrolled will have a t1/2 ≥97 minutes (i.e., the 95th percentile).
• Stable concomitant medications, defined as no changes in regimen for at least 2 weeks prior to Visit 2 (daily adjustments of insulin doses are permitted).
• No use of metoclopramide, erythromycin, domperidone, or other gastrointestinal (GI) motility agents, or anti-emetics for at least 2 weeks prior to Visit 2, and willingness to remain off these medications (except as used as part of protocol-specific rescue medication) during the course of the clinical trial.
• Body mass index >18 kg/m2.
• If female, has a negative serum or urine pregnancy test and is not lactating. For females able to bear children, a hormonal (i.e., oral, implantable, or injectable) and single-barrier method, or a double-barrier method of birth control must be used throughout the study. Female patients unable to bear children must have this documented in the electronic case report form (eCRF) (i.e., tubal ligation, hysterectomy, or post-menopausal [defined as a minimum of 1 year since the last menstrual period]). Post-menopausal status will be confirmed by measurement of follicle stimulating hormone (FSH).
• Able to provide written informed consent prior to any study procedures and willing and able to comply with study procedures.

Additional inclusion criteria for randomization after the 2-week single-blind placebo run-in period:

• Compliance with the completion of the Diabetic Gastroparesis Symptom Severity Diary (DGSSD) and study drug injections, defined as approximately 80% diary completions and approximately 80% administration of injections, during the 2-week single-blind placebo run-in period. For those patients whose compliance is measured to be <80%, the final decision to randomize a patient will be made by the Investigator and the Sponsor (or designee).
• At least one vomiting episode at any time during the 2-week single-blind placebo run-in period, as recorded in the DGSSD.

Exclusion Criteria

• Currently receiving parenteral feeding or presence of a nasogastric or other enteral tube [e.g., Percutaneous Endoscopic Gastrostomy (PEG) tube] for feeding or decompression.
• History of gastric surgery such as fundoplication, gastrectomy, gastric pacemaker placement, vagotomy, or bariatric procedure. (A history of diagnostic endoscopy is not exclusionary.)
• History of pyloric injection of botulinum toxin within 6 months of screening.
• Patients with clinical suspicion of upper GI obstruction (e.g., peptic stricture) must have been evaluated per standard of care and obstruction ruled out before screening.
• Currently taking opiates, or expecting to use opiates during the course of the clinical trial.
• Currently taking Glucagon-like peptide-1 (GLP-1) agonists, Sodium-glucose co-transporter 2 (SGLT2) inhibitors or pramlintide.
• Allergic or intolerant of egg, wheat, milk, or algae, as these are components of the Gastric emptying breath test (GEBT) study meal. (Gluten-free crackers can be provided.)
• History of anorexia nervosa, binge-eating, or bulimia within 5 years of screening.
• Alanine aminotransferase (ALT) or aspartate aminotransferase (AST) > 2 × upper limit of normal (ULN) at Visit 1.
• History of intestinal malabsorption or pancreatic exocrine disease.
• Requires hemodialysis or has end-stage renal disease.
• History of human immunodeficiency virus (HIV) infection.
• Clinically significant neurologic or psychiatric disorders that are likely to impact compliance with protocol requirements.
• Poor venous access or inability to tolerate venipuncture.
• Participation in a clinical study within the 30 days prior to dosing in the present study.
• Any other reason that, in the Investigator's opinion, would confound proper interpretation of the study or expose a patient to unacceptable risk, including renal, hepatic or cardiopulmonary disease, or significant acute electrocardiogram (ECG) abnormalities.

Study & Design

• Study Type: INTERVENTIONAL
• Study Design: PARALLEL

Arm && Interventions

Group	Intervention	Description
Relamorelin 10 μg	Relamorelin	Relamorelin 10 microgram (μg) was administered subcutaneously (SC) by injection twice daily (BID) for 12 weeks.
Relamorelin 30 μg	Relamorelin	Relamorelin 30 μg was administered SC by injection BID for 12 weeks.
Relamorelin 100 μg	Relamorelin	Relamorelin 100 μg was administered SC by injection BID for 12 weeks.
Placebo	Placebo	Placebo-matching relamorelin was administered SC by injection BID for 12 weeks.

Primary Outcome Measures

Name	Time	Method
Change From Baseline to Week 12 in Weekly Vomiting Episodes	7 days prior to Day 1 for Baseline to 7 days prior to Week 12	Vomiting episodes were assessed via the Diabetic Gastroparesis Symptoms Severity Diary (DGSSD). The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of Diabetic Gastroparesis (DG) (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Each day, the participant recorded the number of vomiting episodes in the past 24 hours in the diary. Higher scores indicate more vomiting episodes. Weekly scores were averaged across the 12 weeks period. A negative change from Baseline indicates improvement.

Secondary Outcome Measures

Name	Time	Method
Change From Baseline to Week 12 in Weekly DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal Pain)	7 days prior to Day 1 for Baseline to 7 days prior to Week 12	The DGSSD is a 7-item, participant-reported daily diary designed to assess the severity of 6 core signs and symptoms of DG (nausea, abdominal pain, postprandial fullness, bloating, vomiting, and early satiety) and the frequency of vomiting episodes. Severity of nausea, bloating and abdominal pain, were assessed on a numerical rating scale of 0 to 10, with 0 equating to "no" (symptom) and 10 equating to "worst possible" (symptom). Early satiety was assessed on a 5-item scale with 1 being "Only 1 or 2 bites" and 5 being "All of a normal-sized meal"; symptom severity scores for this item were reversed and normalized to a range 0 to 10 for the development of the DGSSD 4-symptom Composite Score. The DGSSD 4-symptom Composite Score (Nausea, Bloating, Early Satiety, Abdominal pain) range is 0 to 40. Higher scores indicate worse condition. Weekly scores were averaged across 12 weeks period. A negative change from Baseline indicates improvement.
Change From Baseline to Week 12 for Gastric Emptying (GE) as Measured by the Gastric Emptying Breath Test (GEBT) Half-time	Baseline (Day 1) to Week 12	GE was measured via the GEBT and was reported as a time to half (t1/2) of the theoretical total GE. GEBT is a non-radioactive stable isotope breath test intended for measurement of GE of solids in participants. A negative change from Baseline indicates improvement.

Trial Locations

Locations (90)

Digestive Health Specialist of the Southeast; 🇺🇸 Dothan, Alabama, United States

Desert Sun Clinical Research; 🇺🇸 Tucson, Arizona, United States

Adobe Clinical Research; 🇺🇸 Tucson, Arizona, United States

Harrisburg Family Medical Center; 🇺🇸 Harrisburg, Arkansas, United States

Arkansas Primary Care Clinic; 🇺🇸 Little Rock, Arkansas, United States

Preferred Research Partners, Inc.; 🇺🇸 Little Rock, Arkansas, United States

TriWest Research Associates; 🇺🇸 El Cajon, California, United States

Torrance Clinical Research Institute Inc.; 🇺🇸 Lomita, California, United States

Axis Clinical Trials; 🇺🇸 Los Angeles, California, United States

Inland Empire Liver Foundation; 🇺🇸 Rialto, California, United States

Scroll for more (80 remaining)